Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2404514 | Vaccine | 2010 | 5 Pages |
Abstract
Pneumococcal type 1 pilus proteins have been proposed as potential vaccine candidates. Following conjugate pneumococcal vaccination, the prevalence of the pneumococcal type 1 pilus declined dramatically, a decline associated with the elimination of vaccine-type (VT) strains. Here we show that between 2004 and 2007, there has been a significant increase in pilus prevalence, now exceeding rates from the pre-conjugate vaccine era. This increase is primarily due to non-VT strains. These emerging piliated non-VT strains are mostly novel clones, with some exceptions. The rise in pilus type 1 frequency across multiple distinct genetic backgrounds suggests that the pilus may confer an intrinsic advantage.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Gili Regev-Yochay, William P. Hanage, Krzysztof Trzcinski, Sheryl L. Rifas-Shiman, Grace Lee, Andrew Bessolo, Susan S. Huang, Stephen I. Pelton, Alexander J. McAdam, Jonathan A. Finkelstein, Marc Lipsitch, Richard Malley,